Journal
PHARMACEUTICALS
Volume 8, Issue 2, Pages 230-249Publisher
MDPI
DOI: 10.3390/ph8020230
Keywords
chimeric antigen receptor; suicide gene; safety switch; adoptive immunotherapy; cell therapy
Categories
Ask authors/readers for more resources
T-cells genetically redirected with a chimeric antigen receptor (CAR) to recognize tumor antigens and kill tumor cells have been infused in several phase 1 clinical trials with success. Due to safety concerns related to on-target/off-tumor effects or cytokine release syndrome, however, strategies to prevent or abate serious adverse events are required. Pharmacologic therapies; suicide genes; or novel strategies to limit the cytotoxic effect only to malignant cells are under active investigations. In this review, we summarize results and toxicities of investigations employing CAR redirected T-cells, with a focus on published strategies to grant safety of this promising cellular application.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available